NutraPlus to manufacture commercial drugs at Tarapur Plant
Drug firm NutraPlus India will produce its active pharmaceutical ingredient (API) facility at Tarapur plant in Maharashtra Drug firm NutraPlus India has announced its plans to start the commercial production at its multi-purpose active pharmaceutical ingredient (API) facility at Tarapur plant in Maharashtra from September this year. The API plant has a total installed capacity of 360 MT per...
Login or Register to read the full article
Drug firm NutraPlus India will produce its active pharmaceutical ingredient (API) facility at Tarapur plant in Maharashtra
Drug firm NutraPlus India has announced its plans to start the commercial production at its multi-purpose active pharmaceutical ingredient (API) facility at Tarapur plant in Maharashtra from September this year. The API plant has a total installed capacity of 360 MT per annum of various kinds of high-end multi speciality products in therapeutic and analgesic segment of pharma industry, as confirmed by the company to PTI.
"The company will start commercial production from first week of September, 2015 at plant N-92, MIDC Tarapur Maharashtra," NutraPlus India Ltd said in a BSE filing.
The products to be produced at the plant are used by various pharma formulation units to manufacture therapeutic and analgesic products, NutraPlus India said.
Shares of NutraPlus India were trading at Rs 270 apiece in the afternoon trade on BSE, up 6.47 per cent.
Drug firm NutraPlus India has announced its plans to start the commercial production at its multi-purpose active pharmaceutical ingredient (API) facility at Tarapur plant in Maharashtra from September this year. The API plant has a total installed capacity of 360 MT per annum of various kinds of high-end multi speciality products in therapeutic and analgesic segment of pharma industry, as confirmed by the company to PTI.
"The company will start commercial production from first week of September, 2015 at plant N-92, MIDC Tarapur Maharashtra," NutraPlus India Ltd said in a BSE filing.
The products to be produced at the plant are used by various pharma formulation units to manufacture therapeutic and analgesic products, NutraPlus India said.
Shares of NutraPlus India were trading at Rs 270 apiece in the afternoon trade on BSE, up 6.47 per cent.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd